Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
709 stopped studies mapped to Hepatopancreatobiliary Carcinoma and descendants · 93% state a reason
Over the 709 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03818165 | Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma…(AntiCEA_CART) | Phase 1 | terminated | Jan 28, 2019 | Sorrento Therapeutics, Inc. | Limited enrollment. | Enrollment / accrual |
| NCT03582618 | CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma | Phase 2 | terminated | Jul 11, 2018 | TaiRx, Inc. | The study has been terminated due to slow enrollment | Enrollment / accrual |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies -… | Phase 1 / Phase 2 | terminated | Mar 19, 2015 | Incyte Corporation | not stated | Not stated |
| NCT01433016 | Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI(OBT for HCC) | Phase 2 | terminated | Sep 13, 2011 | Meridian Bioscience, Inc. | Due to budgetary issues, the company has decided to focus on other applications at this stage. | Funding |
| NCT01381211 | Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of…(TRACE) | Phase 2 | terminated | Jun 27, 2011 | University Hospital, Ghent | based on interim analysis results | Efficacy / futility |
| NCT03781960 | Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma | Phase 2 | terminated | Dec 20, 2018 | Abramson Cancer Center at Penn Medicine | Safety letter from sponsor | Safety / toxicity |
| NCT04178642 | The Impact on Hepatic Recurrence After Adjuvant Chemotherapy With Intraarterial Infusion…(LIDA-ADJ) | Phase 2 | withdrawn | Nov 26, 2019 | University Hospital, Montpellier | no participants enrolled | Enrollment / accrual |
| NCT05327738 | Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of… | Phase 2 | withdrawn | Apr 14, 2022 | OHSU Knight Cancer Institute | Due to inadequate funding. This trial may open as a new clinical trial at a later date, pending… | Funding |
| NCT05380557 | ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic…(ARTEMIS) | — | terminated | May 19, 2022 | Invitae Corporation | Low site engagement and accrual | Enrollment / accrual |
| NCT04076761 | Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma(MOCHA) | Phase 2 | terminated | Sep 3, 2019 | Sunnybrook Health Sciences Centre | Lack of Funding | Funding |
| NCT04304781 | Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer | Phase 1 | terminated | Mar 11, 2020 | Danielle Kim Turgeon | Terminated due to lack of dimer. | Other (stated, no rule matched) |
| NCT04400903 | Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer | — | terminated | May 26, 2020 | OHSU Knight Cancer Institute | Slow accrual | Enrollment / accrual |
| NCT01167374 | Carbon Ion Radiotherapy for Hepatocellular Carcinoma(PROMETHEUS-01) | N/A | terminated | Jul 22, 2010 | University Hospital Heidelberg | Slow recruitment rate | Enrollment / accrual |
| NCT02415036 | Melphalan for Use With the Hepatic Delivery System Treatment in Patients With… | Phase 2 | terminated | Apr 14, 2015 | Delcath Systems Inc. | Limited enrollment | Enrollment / accrual |
| NCT05093608 | SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced… | Phase 1 | terminated | Oct 26, 2021 | H. Lee Moffitt Cancer Center and Research Institute | Loss of funding | Funding |
| NCT03723915 | Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer | Phase 2 | terminated | Oct 30, 2018 | Northwestern University | The total accrual goal of 34 patients was not met. Stage 1 of the study did not meet the interim… | Efficacy / futility |
| NCT04985136 | A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice… | Phase 3 | terminated | Aug 2, 2021 | Jiangsu HengRui Medicine Co., Ltd. | Sponsor R \& D Strategy Adjustment | Sponsor / business decision |
| NCT03945799 | A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk… | Phase 1 / Phase 2 | terminated | May 10, 2019 | Zhejiang University | The study has gotten preliminary results and stopped advanced. | Other (stated, no rule matched) |
| NCT03353181 | Application of Endoscopic Scissors Cutting ENBD Tube in the Treatment of Malignant Hilar…(ENBD) | N/A | withdrawn | Nov 27, 2017 | Changhai Hospital | Failure to recruit patients | Enrollment / accrual |
| NCT04632199 | Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent… | Phase 1 | withdrawn | Nov 17, 2020 | Ipsen | Business decision not related to any safety or tolerability concern | Safety / toxicity |
| NCT03998033 | Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma(ET-109) | Phase 1 | terminated | Jun 25, 2019 | Eureka Therapeutics Inc. | Reallocation of resources to new HCC study. | Other (stated, no rule matched) |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
| NCT01525069 | Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic… | Phase 1 | terminated | Feb 2, 2012 | Washington University School of Medicine | Equipment that was used in the study was discontinued | Other (stated, no rule matched) |
| NCT04775056 | A Study to Evaluate Vaccines Against COVID-19 in the Real World | — | withdrawn | Mar 1, 2021 | Humanity & Health Medical Group Limited | No sponsor | Other (stated, no rule matched) |
| NCT02446925 | Surefire Catheter Versus Standard End-hole Microcatheter: A Pilot Study | N/A | terminated | May 18, 2015 | Wright State University | Insufficient number of subjects meeting inclusion criteria | Other (stated, no rule matched) |
| NCT02575339 | MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma | Phase 1 / Phase 2 | terminated | Oct 14, 2015 | Kathy Miller | Funder Decision | Other (stated, no rule matched) |
| NCT00746590 | Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma | Phase 2 | terminated | Sep 4, 2008 | BTG International Inc. | Study terminated prematurely by sponsor for business reason. One patient was enrolled. | Enrollment / accrual |
| NCT04306861 | Novel MRI Techniques for Pancreatic Cancer | — | withdrawn | Mar 13, 2020 | Beth Israel Deaconess Medical Center | Enrollment and other trial activities have temporarily paused due to COVID-19 and are expected to… | COVID-19 / pandemic |
| NCT04717687 | Pilot Study on the Evaluation of Irreversible Electroporation Technique in Infiltrating…(HOPE) | N/A | withdrawn | Jan 22, 2021 | Poitiers University Hospital | No enrollment | Enrollment / accrual |
| NCT03402607 | Trial Comparing PLA to HIGRT (PROVE-HCC)(PROVE-HCC) | N/A | terminated | Jan 18, 2018 | Duke University | Lack of enrollment | Enrollment / accrual |
| NCT03012282 | CT Perfusion Images in Assessing Treatment Response in Patients With Pancreatic Cancer | N/A | terminated | Jan 6, 2017 | University of Washington | Termination due to slow accrual | Enrollment / accrual |
| NCT03634683 | A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation | Phase 1 / Phase 2 | withdrawn | Aug 16, 2018 | Lion TCR Pte. Ltd. | Major changes in manufacturing process and investigational product | Drug supply |
| NCT04895046 | Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma | Phase 2 | withdrawn | May 20, 2021 | Walid Shaib, MD | Funder decision | Other (stated, no rule matched) |
| NCT01402908 | A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC…(PATRON) | Phase 3 | terminated | Jul 26, 2011 | Cellxpert Biotechnology Corp. | Due to Interim Analysis and business concerns | Efficacy / futility |
| NCT03956940 | Analysis of cfDNA in Patients With Hepatocarcinoma and Treated by Sorafenib or Regorafenib(HELP) | N/A | terminated | May 21, 2019 | Institut du Cancer de Montpellier - Val d'Aurelle | Change of the scientific and medical context that is no longer favorable to our study. This has… | Other (stated, no rule matched) |
| NCT01371240 | Secretin-Assisted Computed Tomography Scan and Magnetic Resonance Imaging in Improving… | Early Phase 1 | withdrawn | Jun 10, 2011 | University Hospitals Cleveland Medical Center | Study never started | Other (stated, no rule matched) |
| NCT04546828 | A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy… | Phase 2 | withdrawn | Sep 14, 2020 | Samsung Medical Center | problem of sponsor | Other (stated, no rule matched) |
| NCT04178460 | A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 26, 2019 | Zai Lab (Shanghai) Co., Ltd. | This termination decision is a business decision and is not due to any safety concerns. | Safety / toxicity |
| NCT04190498 | Sleep Apnoea Syndrome and Hepatocellular Carcinoma(ECHAPS) | — | withdrawn | Dec 9, 2019 | University Hospital, Grenoble | the possibility of obtaining histological data is too low due to the lack of availability of… | Other (stated, no rule matched) |
| NCT04727541 | Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer(NEOBIL) | Phase 2 | terminated | Jan 27, 2021 | AIO-Studien-gGmbH | Based on results of another phase II study with bintrafusp alfa in combination with gemcitabine… | Enrollment / accrual |
| NCT03059147 | Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced… | Phase 1 | terminated | Feb 23, 2017 | SignalRX Pharmaceuticals, Inc. | Lack of recruitment and sponsor's priority changes | Enrollment / accrual |
| NCT03655613 | APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC… | Phase 1 / Phase 2 | terminated | Aug 31, 2018 | Apollomics (Australia) Pty. Ltd. | Study terminated due to administrative reasons. | Other (stated, no rule matched) |
| NCT04465734 | A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04… | Phase 3 | withdrawn | Jul 10, 2020 | Shanghai Henlius Biotech | The trial used sorafenib as a control drug. It's not suitable now(after the A+T has been… | Other (stated, no rule matched) |
| NCT03316222 | Study of GNS561 in Patients With Liver Cancer | Phase 1 / Phase 2 | terminated | Oct 20, 2017 | Genoscience Pharma | only phase 1b was completed and the phase 2 will be an another study, finally | Other (stated, no rule matched) |
| NCT02850874 | HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma | Phase 2 | withdrawn | Aug 1, 2016 | Wake Forest University Health Sciences | no accrual rate | Enrollment / accrual |
| NCT02102022 | Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on… | Phase 1 / Phase 2 | terminated | Apr 2, 2014 | Polaris Group | not stated | Not stated |
| NCT02704130 | TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma | N/A | terminated | Mar 9, 2016 | Wake Forest University Health Sciences | Lack of funding | Funding |
| NCT04480190 | Neoadjuvant Therapy in Biliary Adenocarcinoma | Phase 1 | withdrawn | Jul 21, 2020 | Jordan Kharofa | Difficulty accruing | Enrollment / accrual |
| NCT03682744 | CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases… | Phase 1 | withdrawn | Sep 25, 2018 | Sorrento Therapeutics, Inc. | Unable to enroll subjects | Enrollment / accrual |
| NCT03852836 | Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images(BiliFast) | N/A | terminated | Feb 25, 2019 | IHU Strasbourg | COVID Pandemy - recruitment issue | COVID-19 / pandemic |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jan 17, 2023source: clinicaltrials